SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A decrease in the sales to Rs. 5775.40 millions was observed for the quarter ended September 2023. The sales stood at Rs. 6248.30 millions during the similar quarter previous year.The Company's Net profit for the September 2023 quarter have declined marginally to Rs. 345.80  millions as against Rs. 365.80 millions reported during the corresponding quarter ended.Operating profit for the quarter ended September 2023 decreased to 661.60 millions as compared to 702.70 millions of corresponding quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 5775.40 6248.30 -7.57 11691.70 11760.30 -0.58 24979.70 22511.70 10.96
Other Income 7.40 0.90 722.22 13.90 3.30 321.21 22.30 47.80 -53.35
PBIDT 661.60 702.70 -5.85 1387.20 1252.40 10.76 2846.30 3229.50 -11.87
Interest 75.50 82.70 -8.71 153.20 150.60 1.73 325.30 200.60 62.16
PBDT 586.10 620.00 -5.47 1234.00 1101.80 12.00 2521.00 3028.90 -16.77
Depreciation 117.80 119.20 -1.17 235.30 237.50 -0.93 472.90 473.90 -0.21
PBT 468.30 500.80 -6.49 998.70 864.30 15.55 2048.10 2555.00 -19.84
TAX 122.50 135.00 -9.26 257.50 235.00 9.57 520.00 605.00 -14.05
Deferred Tax 12.50 5.00 150.00 20.00 15.00 33.33 -12.50 -50.00 -75.00
PAT 345.80 365.80 -5.47 741.20 629.30 17.78 1528.10 1950.00 -21.64
Equity 919.40 926.00 -0.71 926.00 926.00 0.00 926.00 926.00 0.00
PBIDTM(%) 11.46 11.25 1.86 11.86 10.65 11.41 11.39 14.35 -20.57

Aarti Drugs Share Price

374.60 1.80 (0.48%)
15-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.45
Dr. Reddys Lab 1279.25
Cipla 1381.50
Zydus Lifesciences 1087.75
Lupin 2273.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: